July 29, 2026

2025 BP Guideline Could Reduce Mortality

Modeling of nationally representative US data suggested broader implementation of the AHA/ACC 's 2025 recommendations could expand antihypertensive treatment eligibility and reduce long-term mortality among high-risk adults.

Conexiant

July 29, 2026

Can Statin Muscle Risk Be Predicted?

Researchers developed and externally validated a prediction model estimating 1-, 5-, and 10-year risks of serious muscle disorders among patients potentially eligible for statin therapy.

Conexiant

July 28, 2026

May Lower RFR Signal Repeat Revascularization?

Patients with lower nonischemic resting full-cycle ratio values had more repeat revascularizations despite similar 2-year major cardiovascular event rates.

Conexiant

July 24, 2026

FDA Approves Furoscix ReadyFlow

Clinical data demonstrated achievement of the primary pharmacokinetic endpoint, with urine output and sodium and potassium excretion comparable with those observed with intravenous furosemide, according to MannKind.

Conexiant

July 22, 2026

Uric Acid May Signal Coronary Calcification

The association with coronary artery calcium persisted following extensive adjustment, whereas carotid plaque findings may be largely explained by cardiometabolic risk factors.

Conexiant

July 21, 2026

Four Patterns in End-of-Life Decline?

International cohort study found physical function declined most rapidly before mortality, while socioeconomic status was associated with more favorable multidomain trajectories.

Conexiant

July 20, 2026

AHA: Coffee Need Not Be Avoided in AF

Moderate coffee consumption generally appeared safe for most adults, but randomized evidence suggested divergent effects on atrial fibrillation and premature ventricular contractions.

Conexiant

July 17, 2026

FDA Approves New Iohexol Vials

The approval includes additional 300 mg iodine/mL and 350 mg iodine/mL vial presentations.

Conexiant

July 17, 2026

Effect of Socioeconomic Status on SGLT2 Initiation in Heart Failure

A nationwide German claims analysis found lower initiation of guideline-recommended sodium-glucose cotransporter-2 inhibitors among women and patients living in lower-income municipalities.

Conexiant

July 16, 2026

FDA Approves First Oral PCSK9 Inhibitor

Merck reported placebo-adjusted LDL-C reductions of 56% and 59% at week 24 in two phase 3 CORALreef trials supporting the approval.

Conexiant